Ilie SM, et al. - Given that intensive adjuvant chemotherapy regimens have been proposed in triple-negative breast cancer (TNBC) in the absence of postoperative targeted treatments but aggressive treatments are unnecessary for those favorable histologies, researchers attempted to determine the biomarkers assessable by immunohistochemistry, to be proposed as prognostic score for tailoring adjuvant treatment to TNBC patients. They performed a retrospective analysis of 631 cases of breast cancer, primary operated curatively, and followed up for at least 36 months. Based on initial observations, cytokeratin 5/6 (CK5/6) and epithelial cadherin (E-cad) were suggested to be the possible core biomarkers that could enable a cost-effective prognostic assessment of primary operable TNBC patients.